Importance: Caregivers play a protective role in emergency department (ED) care transitions. When the demands of caregiving result in caregiver burden, ED returns can ensue. Objective: We developed models describing how caregiver burden may predict ED revisits and admissions up to thirty days after discharge. Design: This prospective cohort study nested within the LEARNING WISDOM clinical trial included older adults and their caregivers who underwent a transition of care from one of four EDs in Quebec, Canada between January 1st, 2019, and December 21st, 2021. Setting: This study occurred within an integrated health multi-site organization consisting of four acute care hospitals. Participants: Patients aged 65 years or older who were discharged back to the community from the ED observation unit after being triaged to a stretcher on their index visit. Exposure: Caregiver burden, as collected using the brief twelve-item Quebec French version of the Zarit Brief Burden Interview (ZBI). Main Outcomes and Measure: Revisits to the ED were defined as a return to any ED in the 4-hospital network within 3, 7, or 30 days of the index visit. Admissions were return visits to the ED within 30 days resulting in hospitalization. Results: Among 1,409 caregiver-patient dyads, ZBI scores averaged 7.33 (SD = 7.11). Most caregivers were women (69%). Caregivers were most often spouses (48%) of patients or children of patients (38%). Among all patients, 5.3% returned to the ED within 3 days, 9.4% returned within 7 days, 20.7% returned within 30 days and 6.2% were admitted within 30 days. Each point increase on the ZBI scale was associated with a 2.8% increase in the odds of a 30-day revisit to the ED (p = 0.03), but not in models with shorter time windows, nor for admissions. ZBI scores on 30-day ED revisits were moderated by the COVID-19 pandemic waves: the first inter-wave period attenuated the association. Conclusions and Relevance: Caregiver burden may modestly predict ED revisits over 30 days. Future studies may enhance the management of ED revisits by predicting the longitudinal impact of caregiver burden on ED use in older adults. Trial Registration: https://clinicaltrials.gov/ct2/show/NCT04093245

The LEARNING WISDOM clinical trial was funded by an Embedded Clinician Salary Award (ECRA) awarded to PMA from the Canadian Institutes for Health Research (CIHR) (#201603), a Fonds de recherche du Québec - Santé (FRQS) Senior Clinical Scholar Award (#283211), and a CIHR Project Grant (#378616). Work on this article was supported by a Master's Award: Canada Graduate Scholarships Award (CIHR) awarded to NG (#202112). The funding bodies had no role in the design of the study, collection, or analysis of the data, interpretation of the results, or writing of the manuscript. The authors do not have any conflicts of interest to declare.

NCT04093245

https://doi.org/10.2196/17363

The LEARNING WISDOM clinical trial was funded by an Embedded Clinician Salary Award (ECRA) awarded to PMA from the Canadian Institutes for Health Research (CIHR) (#201603), a Fonds de recherche du Québec - Santé (FRQS) Senior Clinical Scholar Award (#283211), and a CIHR Project Grant (#378616). Work on this article was supported by a Master's Award: Canada Graduate Scholarships Award (CIHR) awarded to NG (#202112).

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The protocol for this study was approved by the Centre intégré de santé et de services sociaux - Chaudière Appalaches (CISSS-CA, Québec, Canada) Ethics Review Committee (project #2018-462, 2018-007).

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes

Analysis code is consultable in a public repository on GitHub. Please contact the corresponding author for a link to the repository. Anonymized data are available from the corresponding author on reasonable request.